SoFi CEO enters prepaid forward contract on 1.5 million shares
Adam Scott Levy, Chief Financial Officer and Secretary of Mineralys Therapeutics , Inc. (NASDAQ:MLYS), sold a total of 73,328 shares of common stock between July 28 and July 30, 2025. The sales, conducted in multiple transactions, amounted to approximately $1,077,476. The transactions come as the company’s stock has gained over 40% in the past six months, according to InvestingPro data.
On July 28, Levy sold 12,946 shares at a weighted average price of $14.0432, in a range of $14.00 to $14.20. Following this, on July 29, he sold 807 shares at a weighted average price of $14.0048, in a range of $14.00 to $14.01. The sales continued on July 30, with 51,500 shares sold at a weighted average price of $14.7023, in a range of $14.06 to $15.06, and 8,425 shares sold at a weighted average price of $15.0983, in a range of $15.063 to $15.130. Notably, analysts maintain a bullish outlook on MLYS, with a consensus recommendation of 1.44 on InvestingPro.
Following these transactions, Levy directly owns 132,934 shares of Mineralys Therapeutics, Inc. The company maintains strong liquidity with a current ratio of 26.48, and its stock typically moves counter to the market with a beta of -0.31. Get deeper insights into MLYS’s financial health and access exclusive analysis through InvestingPro’s comprehensive research reports.
In other recent news, Mineralys Therapeutics, Inc. announced positive results from its Phase 3 Launch-HTN trial for lorundrostat, an aldosterone synthase inhibitor aimed at treating uncontrolled or treatment-resistant hypertension. The trial, involving 1,083 participants, revealed that lorundrostat significantly reduced systolic blood pressure when added to existing treatments. Additionally, Mineralys reported favorable outcomes from its Phase 2 Explore-CKD trial, where lorundrostat demonstrated a significant reduction in systolic blood pressure and improved kidney function markers in patients with chronic kidney disease. Following these results, H.C. Wainwright reiterated a Buy rating with a $42.00 price target, citing the drug’s potential for a robust NDA submission. Meanwhile, Jefferies maintained a Hold rating and a $15.00 price target, noting comparable efficacy and safety profiles between Mineralys’ and competitor AstraZeneca (NASDAQ:AZN)’s aldosterone synthase inhibitors. These developments reflect Mineralys’ ongoing progress in addressing hypertension and related conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.